AU2020211000B2 - Stable solid dispersions of B-RAF kinase dimer inhibitor, methods of preparation, and uses therefor - Google Patents

Stable solid dispersions of B-RAF kinase dimer inhibitor, methods of preparation, and uses therefor

Info

Publication number
AU2020211000B2
AU2020211000B2 AU2020211000A AU2020211000A AU2020211000B2 AU 2020211000 B2 AU2020211000 B2 AU 2020211000B2 AU 2020211000 A AU2020211000 A AU 2020211000A AU 2020211000 A AU2020211000 A AU 2020211000A AU 2020211000 B2 AU2020211000 B2 AU 2020211000B2
Authority
AU
Australia
Prior art keywords
compound
hpmcas
solid dispersion
weight ratio
amorphous solid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020211000A
Other languages
English (en)
Other versions
AU2020211000A1 (en
Inventor
Huangbin SUN
Guoliang Zhang
Changyou Zhou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BeOne Medicines I GmbH
Original Assignee
BeOne Medicines I GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BeOne Medicines I GmbH filed Critical BeOne Medicines I GmbH
Publication of AU2020211000A1 publication Critical patent/AU2020211000A1/en
Application granted granted Critical
Publication of AU2020211000B2 publication Critical patent/AU2020211000B2/en
Assigned to BEONE MEDICINES I GMBH reassignment BEONE MEDICINES I GMBH Request for Assignment Assignors: BEIGENE, LTD.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Dispersion Chemistry (AREA)
AU2020211000A 2019-01-25 2020-01-23 Stable solid dispersions of B-RAF kinase dimer inhibitor, methods of preparation, and uses therefor Active AU2020211000B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2019073254 2019-01-25
CNPCT/CN2019/073254 2019-01-25
CN2019095227 2019-07-09
CNPCT/CN2019/095227 2019-07-09
PCT/CN2020/073944 WO2020151756A1 (en) 2019-01-25 2020-01-23 Stable solid dispersions of b-raf kinase dimer inhibitor, methods of preparation, and uses therefor

Publications (2)

Publication Number Publication Date
AU2020211000A1 AU2020211000A1 (en) 2021-08-12
AU2020211000B2 true AU2020211000B2 (en) 2025-11-06

Family

ID=71735582

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020211000A Active AU2020211000B2 (en) 2019-01-25 2020-01-23 Stable solid dispersions of B-RAF kinase dimer inhibitor, methods of preparation, and uses therefor

Country Status (14)

Country Link
US (1) US12582604B2 (https=)
EP (1) EP3914591A4 (https=)
JP (2) JP7591504B2 (https=)
KR (1) KR20210120039A (https=)
CN (1) CN113330011A (https=)
AU (1) AU2020211000B2 (https=)
BR (1) BR112021014563A2 (https=)
CA (1) CA3123476A1 (https=)
IL (1) IL284636A (https=)
MX (1) MX2021008884A (https=)
SG (1) SG11202107849RA (https=)
TW (2) TWI909513B (https=)
WO (1) WO2020151756A1 (https=)
ZA (1) ZA202104032B (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111484490B (zh) * 2019-01-25 2024-07-09 百济神州有限公司 适合大规模生产b-raf激酶二聚体抑制剂的方法
TWI909513B (zh) 2019-01-25 2025-12-21 英屬開曼群島商百濟神州有限公司 作為ｂ-ｒａｆ激酶二聚體抑制劑之化合物及其製備方法
WO2022146022A1 (ko) * 2020-12-29 2022-07-07 주식회사 티씨노바이오사이언스 엑토뉴클레오티드 피로포스파타아제-포스포디에스터라아제의 저해 활성을 갖는 신규한 나프티리딘온 유도체 및 이들의 용도
KR102889693B1 (ko) 2021-09-08 2025-11-20 주식회사 엘지에너지솔루션 배터리 진단 장치, 배터리 관리 시스템, 배터리 팩, 전기 차량 및 배터리 진단 방법
CN114366717B (zh) * 2022-01-11 2023-06-09 四川农业大学 一种基于egcg纳米粒的肠溶固体分散体颗粒、制备方法及其应用
WO2023240178A1 (en) * 2022-06-08 2023-12-14 Mapkure, Llc Methods of treating cancer with a b-raf inhibitor
KR20250069903A (ko) * 2022-09-26 2025-05-20 맵큐어, 엘엘씨 암 치료를 위한 B-Raf 저해제와 항-EGFR 항체의 조합물
JP2026507361A (ja) * 2023-03-10 2026-03-02 エスティー ファーム カンパニー リミテッド 新規固体分散体およびその製造方法
TW202515875A (zh) 2023-10-12 2025-04-16 瑞士商百濟神州瑞士有限責任公司 包含b-raf激酶二聚體抑制劑之固體形式、其製備方法及用途
WO2025252204A1 (en) * 2024-06-07 2025-12-11 Beigene (Suzhou) Co., Ltd. Amorphous solid dispersions of a braf inhibitor

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010114928A2 (en) * 2009-04-03 2010-10-07 F.Hoffmann-La Roche Ag Compositions and uses thereof
WO2014114575A1 (en) * 2013-01-22 2014-07-31 F. Hoffmann-La Roche Ag Pharmaceutical composition with improved bioavailability
WO2014206343A1 (en) * 2013-06-28 2014-12-31 Beigene, Ltd. Fused tricyclic urea compounds as raf kinase and/or raf kinase dimer inhibitors

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6350786B1 (en) 1998-09-22 2002-02-26 Hoffmann-La Roche Inc. Stable complexes of poorly soluble compounds in ionic polymers
ES2306646T3 (es) 1999-02-09 2008-11-16 Pfizer Products Inc. Composiciones de farmacos basicos con biodisponibilidad incrementada.
SE0100733D0 (sv) 2001-03-05 2001-03-05 Medivir Ab Non-nucleoside reverse transcriptase inhibitors
EP1534276B1 (en) 2002-09-05 2008-11-05 Medivir AB Non-nucleoside reverse transcriptase inhibitors
CA2550361C (en) 2003-12-19 2014-04-29 Prabha Ibrahim Compounds and methods for development of ret modulators
US7618964B2 (en) 2004-12-23 2009-11-17 Hoffmann-La Roche Inc. Benzamide derivatives, their manufacture and use as pharmaceutical agents
CN101365682A (zh) 2005-12-08 2009-02-11 千禧药品公司 具有激酶抑制活性的双环化合物
ATE552245T1 (de) 2006-05-15 2012-04-15 Merck Sharp & Dohme Antidiabetische bicyclische verbindungen
JP2010502660A (ja) 2006-09-06 2010-01-28 エフ．ホフマン−ラ ロシュ アーゲー プロテインキナーゼインヒビターとしてのヘテロアリール誘導体
PE20081581A1 (es) 2006-12-21 2008-11-12 Plexxikon Inc COMPUESTOS PIRROLO[2,3-b]PIRIDINAS COMO MODULADORES DE QUINASA
WO2008079909A1 (en) 2006-12-21 2008-07-03 Plexxikon, Inc. Pyrrolo [2,3-b] pyridines as kinase modulators
CN101702878B (zh) 2007-05-11 2012-11-28 弗·哈夫曼-拉罗切有限公司 可溶性差的药物的药物组合物
JP2010533729A (ja) 2007-07-17 2010-10-28 プレキシコン，インコーポレーテッド キナーゼ調節のための化合物と方法、及びそのための適応
SI2947072T1 (sl) * 2008-03-17 2017-03-31 Ambit Biosciences Corporation 1-(3-(6,7-dimetoksikinazolin-4-iloksi)fenil)-3-(5-1,1,1-trifluoro-2- metilpropan-2-il)izoksazol-3-il)urea kot modulator raf kinaze pri zdravljenju rakavih bolezni
JO3101B1 (ar) 2008-12-02 2017-09-20 Takeda Pharmaceuticals Co مشتقات بنزوثيازول كعوامل مضادة للسرطان
US20100197924A1 (en) 2008-12-22 2010-08-05 Millennium Pharmaceuticals, Inc. Preparation of aminotetralin compounds
US20120157453A1 (en) * 2009-08-28 2012-06-21 Genentech, Inc. Raf inhibitor compounds and methods of use thereof
WO2011092088A1 (en) 2010-01-27 2011-08-04 Nerviano Medical Sciences S.R.L. Sulfonamido derivatives of 3,4-diarylpyrazoles as protein kinase inhibitors
WO2011115069A1 (ja) 2010-03-19 2011-09-22 第一三共株式会社 結晶の網羅的探索
KR101911972B1 (ko) * 2011-02-07 2018-10-25 플렉시콘 인코퍼레이티드 키나제 조절을 위한 화합물 및 방법, 및 그에 대한 적응증
US9273046B2 (en) 2011-12-31 2016-03-01 Beigene, Ltd. Fused tricyclic compounds as Raf kinase inhibitors
TR201904980T4 (tr) * 2012-08-07 2019-05-21 Novartis Ag Bir B-Raf inhibitörü, bir EGFR inhibitörü ve isteğe bağlı olarak bir PI3K-alfa inhibitörü içeren farmasötik kombinasyonlar.
JP2014189462A (ja) 2013-03-27 2014-10-06 Osaka Univ 結晶製造方法、準安定形結晶、医薬の製造方法および医薬
US9670231B2 (en) * 2013-06-28 2017-06-06 Beigene, Ltd. Fused tricyclic amide compounds as multiple kinase inhibitors
WO2015152433A1 (en) * 2014-03-31 2015-10-08 Hanmi Pharm. Co., Ltd. Amorphous solid dispersion comprising paclitaxel, tablet comprising the same, and method for preparing the same
TWI909513B (zh) 2019-01-25 2025-12-21 英屬開曼群島商百濟神州有限公司 作為ｂ-ｒａｆ激酶二聚體抑制劑之化合物及其製備方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010114928A2 (en) * 2009-04-03 2010-10-07 F.Hoffmann-La Roche Ag Compositions and uses thereof
WO2014114575A1 (en) * 2013-01-22 2014-07-31 F. Hoffmann-La Roche Ag Pharmaceutical composition with improved bioavailability
WO2014206343A1 (en) * 2013-06-28 2014-12-31 Beigene, Ltd. Fused tricyclic urea compounds as raf kinase and/or raf kinase dimer inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WANG , RUYI; LIU, YI: "Application of Hydroxypropyl Methylcellulose Acetate Succinate to Preparation of Solid Dispersions", CHINESE JOURNAL OF PHARMACEUTICALS, vol. 47, no. 1, 2016, pp 111 - 116, *

Also Published As

Publication number Publication date
US12582604B2 (en) 2026-03-24
BR112021014563A2 (pt) 2021-10-05
JP7591504B2 (ja) 2024-11-28
ZA202104032B (en) 2022-08-31
EP3914591A1 (en) 2021-12-01
IL284636A (en) 2021-08-31
SG11202107849RA (en) 2021-08-30
CA3123476A1 (en) 2020-07-30
EP3914591A4 (en) 2022-11-09
TWI849043B (zh) 2024-07-21
CN113330011A (zh) 2021-08-31
WO2020151756A1 (en) 2020-07-30
MX2021008884A (es) 2021-08-19
US20220105033A1 (en) 2022-04-07
TWI909513B (zh) 2025-12-21
TW202444718A (zh) 2024-11-16
KR20210120039A (ko) 2021-10-06
AU2020211000A1 (en) 2021-08-12
JP2025017374A (ja) 2025-02-05
TW202043225A (zh) 2020-12-01
JP2022517675A (ja) 2022-03-09

Similar Documents

Publication Publication Date Title
AU2020211000B2 (en) Stable solid dispersions of B-RAF kinase dimer inhibitor, methods of preparation, and uses therefor
JP6974534B2 (ja) 縮合複素芳香族ピロリジノンの固体状態形態
EP2262793B1 (en) Nilotinib hci crystalline forms
CN104870427B (zh) Mek抑制剂的制备和包含mek抑制剂的制剂
WO2020053660A1 (en) Solid forms of a bet inhibitor
US20190135806A1 (en) Solid state forms of venetoclax and processes for preparation of venetoclax
CN106661015B (zh) 达沙替尼盐
US20100041885A1 (en) Crystalline forms of sitagliptin phosphate
CN105188699B (zh) 恩杂鲁胺的固态形式及其制备方法和用途
CN102638985A (zh) 地拉罗司的制备方法和地拉罗司多晶型物
CN101198610B (zh) 制备4-[[5-[(环丙基氨基)羰基]-2-甲基苯基]氨基]-5-甲基-N-丙基吡咯并[2,1-f][1,2,4]三嗪-6-甲酰胺的盐的方法及在其中制备的新型稳定形式
CN105517992B (zh) 新型结晶性芳烷基胺化合物及其制造方法
CN116997331A (zh) 固体形式的喹诺酮化合物及其制备方法
CN111484489B (zh) 无定形的b-raf激酶二聚体抑制剂
CN101155802A (zh) 氨基吡咯烷衍生物的晶体及其制备方法
EA047214B1 (ru) СТАБИЛЬНЫЕ ТВЕРДЫЕ ДИСПЕРСИИ ИНГИБИТОРА ДИМЕРА КИНАЗЫ B-Raf, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ИХ ПРИМЕНЕНИЯ
EA052614B1 (ru) Стабильные твердые дисперсии ингибитора димера киназы b-raf, способы их получения и их применения
WO2019210511A1 (zh) 一种s1p1受体激动剂的加成盐及其晶型和药物组合物
HK40055004A (en) Stable solid dispersions of b-raf kinase dimer inhibitor, methods of preparation, and uses therefor
Rajan et al. Novel process for the preparation of methyl N-{(2S)-1-[(4-{3-[5-chloro-2-fluoro-3 (methanesulfonamido) phenyl]-1-(propan-2-yl)-1H-pyrazol-4-yl} pyrimidin-2-yl) amino] propan-2yl} carbamate
CN110167932A (zh) 用于制备(3S，4S)-4-异丙基-6，7-二氢-3H-咪唑并[4，5-c]吡啶-5(4H)-羧酸四氢呋喃-3-基酯的方法

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: BEONE MEDICINES I GMBH

Free format text: FORMER APPLICANT(S): BEIGENE, LTD.

FGA Letters patent sealed or granted (standard patent)